艾吉纳斯 AGEN 深 沪
等待开盘 10-29 09:30:00 美东时间
3.98
-0.170
-4.10%
华盛通- 最 高4.15
- 今 开4.14
- 成交量 15.05万股
- 最 低 3.9688
- 昨 收 4.15
- 总市值 1.27亿
- 52周最高 7.34
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.38
- 委 比 10.26%
- 总股本 3186.41万
- 历史最高 202.5868
- 量 比 0.36
- 振 幅 4.37%
- 历史最低 1.38
- 每 手 1
- 风险率 1.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Orchestra BioMed Announces First Patient Enrollments In Virtue SAB In Treatment Of Coronary ISR Trial
Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release sirolimus
10-27 21:04
【山证汽车】汽车智能驾驶专题（一）：智驾已是“必答题”，低阶配置平权与高阶功能落地共振
登录新浪财经APP 搜索【信披】查看更多考评等级 投资要点 近年来，智能已经是各家汽车企业的“必答题”，无论新能源、燃油车智能功能渗透率正在快...
10-22 08:45
Agenus Releases New Data From Its botensilimab And balstilimab Combination Showing Durable Survival Benefits Across Multiple Late-Stage, Treatment-Resistant Cancers And That ~40% Of Patients With Very Limited Survival Expectation Are Alive At Two Years
Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastasesSignals of tumor agnostic benefit observedTumor types included CRC, sarcoma, ovarian, NSCLC,
10-17 20:10
人工智能企业、网络大V、平台方与监管部门同台，V聚场内多方共话AI技术发展新未来
转自：上海杨浦 “每月在B站观看AI内容用户有1.4亿，95后用户占比80％以上……”“AIGC浪潮下内容创作的机遇与挑战在哪里？”10月10日下午，由上海市委...
10-12 11:05
Agenus Secures $10M Promissory Note with Zydus
Agenus ( ($AGEN) ) has provided an update. On October 8, 2025, Agenus Inc. ente...
10-10 04:30
【明日主题前瞻】低空经济发展火热，今年来eVTOL领域大单频频出现
【今日导读】 低空经济发展火热，今年来eVTOL领域大单频频出现 阿里团队发布全新终端AI智能体iFlow CLI 台积电2纳米制程价格拟提涨至少5...
09-24 18:25
Agenus Faces CFIUS Review Delay in Zydus Deal
Agenus ( ($AGEN) ) has provided an announcement. On June 3, 2025, Agenus and Zy...
09-24 05:28
快讯 | Agenus公司 - 与Zydus Pharmaceuticals（美国）的交易完成时间推迟至2025年第四季度 - SEC文件
Agenus Inc - Closing of Deals With Zydus Pharmaceuticals (USA) Shifted to Q4 20...
09-24 05:14
Agenus Says Investigational Combination BOT/BAL Now Available To Eligible Patients With Refractory MSS mCRC Under France's Compassionate Access Framework
Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable
09-09 19:45
